Eli Lilly

News

Lilly ramps up Irish manufacturing investment by $1bn

Eli Lilly has added $1 billion to its investment plan for a new manufacturing facility in Ireland that will be used to produce its Alzheimer's therapy donanemab.

News

Genetic Leap image of Genetic Intelligence

Lilly adds to genetic meds push with Genetic Leap alliance

In its second R&D alliance this week, Eli Lilly has formed a partnership with Genetic Leap, a startup that focuses on applying artificial intelligence to the discovery of RNA-targeted t

News

Samir Ounzain, CEO and co-founder of Haya Therapeutics

Lilly to hunt non-coding DNA for obesity drugs in $1bn deal

Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA.

News

Lilly launches single-dose Zepbound to ease self-pay access

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford

News

Pfizer joins Lilly in direct-to-consumer drive

Pfizer has become the latest big pharma group to launch a web-based platform that opens up a direct-to-consumer channel for medicines access.

News

Lilly says tirzepatide staves off diabetes in phase 3 trial

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and ob

Lilly ramps up Irish manufacturing investment by $1bn

Lilly adds to genetic meds push with Genetic Leap alliance

Lilly to hunt non-coding DNA for obesity drugs in $1bn deal

Lilly launches single-dose Zepbound to ease self-pay access

Pfizer joins Lilly in direct-to-consumer drive

Lilly says tirzepatide staves off diabetes in phase 3 trial

Alzheimer's biotech Korsana to go public via reverse merger

Using AI-driven synthetic personas to take your insights fur...

Eli Lilly

Editor's Picks